Navigation Links
Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Date:10/4/2007

Data Safety Monitoring Board Recommends Continuing Study

NEW YORK, Oct. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness.

African sleeping sickness is a fatal, vector-borne parasitic disease spread by tsetse flies that threatens approximately 60 million people in sub- Saharan Africa. Current treatments for the first stage of the disease include pentamidine and suramin. Both of these intravenous drugs are associated with reported toxic side effects. If approved, pafuramidine could become the first safe and effective oral treatment for first-stage African sleeping sickness.

Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer stated, "Successfully completing pafuramidine's Phase III interim analysis is a major milestone on the path to registering pafuramidine for treatment of African sleeping sickness. The next major milestone will be to have the remaining patients complete the 12-month follow up protocol and for Immtech to prepare the documents for the NDA submission. We aim to have pafuramidine approved to combat this devastating infectious disease."

Enrollment in this trial was completed earlier in 2007, and all patients are expected to complete
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Ga. , Oct. 31, 2014  Digirad Corporation ... to PDI, Inc. (Nasdaq: PDII ), a ... of Digirad,s proposal to acquire the company.  ... meaningful discussions regarding a transaction and to operate in ... its cash, or take on additional debt, on acquisitions ...
(Date:10/31/2014)... 31, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today reported financial results for the third ... "In the third quarter of ... , M.D., chief executive officer of Semler.  "We ...
(Date:10/31/2014)... , October 31, 2014 Investor-Edge ... MDT ), Abbott Laboratories (NYSE: ABT ... (NYSE: RMD ), and Covidien PLC (NYSE: COV). ... http://investor-edge.com/register . The US markets on Thursday, ... Dow Jones Industrial Average finished at 17,195.42, up 1.30% and ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5
... Aug. 8, 2011 Insmed Incorporated (Nasdaq CM: INSM), a ... six-months ended June 30, 2011. Key Recent ... of data from the open-label phase 2 study of Arikace™ ... (CF) patients with Pseudomonas lung infections ...
... (NYSE Amex: ANX ) today reported financial results ... we head into the second half of the year, we ... into the U.S. market, should it be approved on or ... Brian M. Culley, Chief Executive Officer of ADVENTRX.  "Having a ...
Cached Medicine Technology:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 8ADVENTRX Reports Second Quarter 2011 Financial Results 2ADVENTRX Reports Second Quarter 2011 Financial Results 3ADVENTRX Reports Second Quarter 2011 Financial Results 4ADVENTRX Reports Second Quarter 2011 Financial Results 5ADVENTRX Reports Second Quarter 2011 Financial Results 6ADVENTRX Reports Second Quarter 2011 Financial Results 7
(Date:10/31/2014)... apnea may make it hard for you to remember simple ... your house keys, a small study suggests. Tests on ... -- called spatial memory -- was impaired when sleep apnea ... of sleep weren,t affected. REM sleep is the deepest level ... for the first time that sleep apnea, an increasingly common ...
(Date:10/31/2014)... Hopkins engineers have invented a lab device to give ... complex way that tumor cells spread through the body, ... shedding light on precisely how tumor cells travel, the ... check. , The inventors, from the university,s Whiting School ... details and images from their new system recently in ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
(Date:10/31/2014)... October 31, 2014 Phoenix dentist , ... treatments for November. Whether patients simply need routine care or ... better time than now to get that necessary care. The ... put off routine and even essential treatments due to financial ... substantial savings on any treatments offered by the team at ...
(Date:10/31/2014)... 31, 2014 Adults 65 and ... their Medicare coverage during the current open enrollment ... library for step-by-step guidance, the company announced today. ... on choosing the correct Medicare Advantage plan, understanding ... open enrollment. , “With just one month remaining ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... French . , MONTREAL, December 14, 2010 The first ... to recognize the sound of their parents, voice and the parents ... and newborns admitted to the intensive care unit can be very ... Jan Lariviere, a nurse in the neonatal clinic and the Neonatal ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Most ... United States is funded by states, not the federal government, ... variation in the extent to which states prioritized human embryonic ... in states could likely have been funded under federal government ...
... a woman in New Hampshire have received the first kidney ... Organ Procurement and Transplantation Network (OPTN) that uses a Carnegie ... donors. Both recipients Ken Crowder of St. Louis and ... were willing to donate a kidney but who were medically ...
... (HealthDay News) -- A federal judge ruled Monday that the ... government has no authority to require citizens to buy health ... new legislation, signed into law in March by President Barack ... supporters and opponents of the legislation anticipate the validity of ...
... that alter the activity of genes direct changes to ... control when genes are switched on and off, called epigenetic ... an opening for the cancerous growth of cells. Researchers ... at work on a genome-wide scale in cases of ovarian ...
... HealthDay Reporter , MONDAY, Dec. 13 (HealthDay News) ... may be child,s play, researchers report. A new ... cereals if they,re given a selection of choices at breakfast, ... fruit instead. The 5-to-12-year-olds in the study still ate ...
Cached Medicine News:Health News:Once upon a time in the Intensive Care Unit ... 2Health News:States Now Fund Most Embryonic Stem Cell Research in U.S. 2Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:Ovarian cancer advances when genes are silenced 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 3
3.5 mm blade. Round handle. Designated most popular model or size....
7 mm curved blade. Round handle....
1.5 mm long blade. Square handle....
Double-ended. 0.9 mm x 1 mm blade. Angled at 90 and 120 degrees. Round handle. Designated most popular model or size....
Medicine Products: